Publications
- Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma2018 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia2017 | First Faculty of Medicine, Faculty of Mathematics and Physics
- Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry2016 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial2015 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance2014 | First Faculty of Medicine
- Jumping-like translocation-a rare chromosomal rearrangement in a patient with Burkitt lymphoma/leukemia2014 | First Faculty of Medicine
- Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment2012 | First Faculty of Medicine
- Concurrent tp53 and cdkn2a gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy2020 | First Faculty of Medicine, Second Faculty of Medicine
- A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma2020 | First Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...